These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39384455)

  • 1. PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis.
    Beshr MS; Beshr IA; Al Hayek M; Alfaqaih SM; Abuajamieh M; Basheer E; Wali AK; Ekreer M; Chenfouh I; Khashan A; Hassan ET; Elnaami SM; Elhadi M
    Clin Oncol (R Coll Radiol); 2024 Dec; 36(12):797-808. PubMed ID: 39384455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
    Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
    Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
    Gao X; Ji K; Jia Y; Shan F; Chen Y; Xu N; Jia Z; Liu T; Yang N; Zhong H; Li C; Guo Z; Fan Q; Lin X; Zhang Y; Ren H; Yang H; Yao Z; Liu W; Wang ZM; Li B; Xia M; Shen L; Li Z; Ji J
    Nat Med; 2024 Jul; 30(7):1943-1951. PubMed ID: 38778212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.
    Formica V; Morelli C; Fornaro L; Riondino S; Rofei M; Fontana E; Smyth EC; Roselli M; Arkenau HT
    ESMO Open; 2024 Nov; 9(11):103967. PubMed ID: 39541621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
    Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F
    Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups.
    Leone AG; Mai AS; Fong KY; Yap DWT; Kato K; Smyth E; Moehler M; Seong JTC; Sundar R; Zhao JJ; Pietrantonio F
    ESMO Open; 2024 Nov; 9(11):103962. PubMed ID: 39426081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.
    Goldkuhle M; Kreuzberger N; von Tresckow B; Eichenauer DA; Specht L; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD007110. PubMed ID: 39620432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
    Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Van Cutsem E; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
    Future Oncol; 2024; 20(26):1861-1877. PubMed ID: 38861294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.
    Lei X; Huo W; Xu T; Xu J; Liu M; Liu C; Gu Z
    BMC Gastroenterol; 2024 Nov; 24(1):422. PubMed ID: 39573989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidants for female subfertility.
    Showell MG; Mackenzie-Proctor R; Jordan V; Hart RJ
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD007807. PubMed ID: 32851663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC).
    Landre T; Chouaïd C; Sadaoui N; Bouharati D; Taleb C
    J Chemother; 2024 Dec; 36(8):675-681. PubMed ID: 38303601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.